Millions of patients are affected by hematologic diseases and rare blood disorders, ranging from widespread, chronic conditions to less common illnesses. These diseases often require innovative approaches and a deep understanding of biological processes to develop effective treatments.

Disc Medicine is dedicated to the development of targeted therapies for hematologic diseases and rare blood disorders. The company translates scientific discoveries into treatments designed to save lives, alleviate suffering, and improve the quality of life for patients and their families. Disc Medicine is pioneering new fields of biology to address unmet needs in hematology.

Development of DISC-0974 for anemia of myelofibrosis (MF), with Phase 1b trial data presented at ASH.

Bitopertin development for erythropoietic protoporphyria (EPP), having completed a successful end of Phase 2 meeting with the FDA.

Focus on creating therapies that address a range of hematologic conditions, from rare blood disorders to widespread, chronic disorders.

The primary target audience includes patients suffering from hematologic diseases and rare blood disorders, as well as the healthcare professionals who treat them.